[
    [
        {
            "time": "2018-07-14",
            "original_text": "华大基因应对“大考”：回应“癌变”质疑，收入增长稳定",
            "features": {
                "keywords": [
                    "华大基因",
                    "癌变",
                    "收入增长"
                ],
                "sentiment_score": 0.3,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医疗",
                    "生物科技"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "华大基因应对“大考”：回应“癌变”质疑，收入增长稳定",
                "Correlation": 9,
                "Sentiment": 5,
                "Importance": 8,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 8,
                "Market_Scope": 4,
                "Time_Proximity": 7,
                "Headline_Structure": 8,
                "Source_Recency": 8
            }
        },
        {
            "time": "2018-07-16",
            "original_text": "下周479亿市值限售股解禁，环比增加334.15%",
            "features": {
                "keywords": [
                    "限售股解禁",
                    "市值",
                    "环比增加"
                ],
                "sentiment_score": -0.6,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "全市场"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "下周479亿市值限售股解禁，环比增加334.15%",
                "Correlation": 5,
                "Sentiment": 3,
                "Importance": 7,
                "Impact": 7,
                "Duration": 5,
                "Entity_Density": 3,
                "Market_Scope": 9,
                "Time_Proximity": 9,
                "Headline_Structure": 7,
                "Source_Recency": 9
            }
        },
        {
            "time": "2018-07-15",
            "original_text": "公告精选：珈伟股份澄清从未参与投资“投之家”；上海莱士炒股亏损，半年报预亏6.61亿元~8.73亿元",
            "features": {
                "keywords": [
                    "珈伟股份",
                    "澄清",
                    "上海莱士",
                    "炒股亏损"
                ],
                "sentiment_score": -0.8,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "金融",
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "公告精选：珈伟股份澄清从未参与投资“投之家”；上海莱士炒股亏损，半年报预亏6.61亿元~8.73亿元",
                "Correlation": 4,
                "Sentiment": 3,
                "Importance": 6,
                "Impact": 5,
                "Duration": 4,
                "Entity_Density": 6,
                "Market_Scope": 5,
                "Time_Proximity": 7,
                "Headline_Structure": 6,
                "Source_Recency": 8
            }
        },
        {
            "time": "2018-07-17",
            "original_text": "华大基因回应报道《华大癌变》：会告知受检者无创基因检测的技术局限性",
            "features": {
                "keywords": [
                    "华大基因",
                    "癌变",
                    "技术局限性"
                ],
                "sentiment_score": -0.4,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医疗",
                    "生物科技"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "华大基因回应报道《华大癌变》：会告知受检者无创基因检测的技术局限性",
                "Correlation": 10,
                "Sentiment": 5,
                "Importance": 9,
                "Impact": 8,
                "Duration": 7,
                "Entity_Density": 9,
                "Market_Scope": 3,
                "Time_Proximity": 8,
                "Headline_Structure": 8,
                "Source_Recency": 9
            }
        },
        {
            "time": "2018-07-18",
            "original_text": "华大基因已在相关知情同意书中明确告知无创基因检测技术局限性",
            "features": {
                "keywords": [
                    "华大基因",
                    "知情同意书",
                    "技术局限性"
                ],
                "sentiment_score": -0.2,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医疗",
                    "生物科技"
                ],
                "causal_factor": "true",
                "causal_impact": "neutral",
                "affected_by_time_series": "true",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "华大基因已在相关知情同意书中明确告知无创基因检测技术局限性",
                "Correlation": 9,
                "Sentiment": 6,
                "Importance": 7,
                "Impact": 6,
                "Duration": 6,
                "Entity_Density": 8,
                "Market_Scope": 3,
                "Time_Proximity": 7,
                "Headline_Structure": 5,
                "Source_Recency": 8
            }
        },
        {
            "time": "2018-07-19",
            "original_text": "华大基因发半年度业绩预告：收入同比增长24%至35%",
            "features": {
                "keywords": [
                    "华大基因",
                    "业绩预告",
                    "收入增长"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医疗",
                    "生物科技"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "华大基因发半年度业绩预告：收入同比增长24%至35%",
                "Correlation": 10,
                "Sentiment": 8,
                "Importance": 9,
                "Impact": 9,
                "Duration": 8,
                "Entity_Density": 9,
                "Market_Scope": 4,
                "Time_Proximity": 9,
                "Headline_Structure": 7,
                "Source_Recency": 10
            }
        },
        {
            "time": "2018-07-20",
            "original_text": "华大基因无创产前检测遭质疑：案例较为复杂，不只是技术问题",
            "features": {
                "keywords": [
                    "华大基因",
                    "无创产前检测",
                    "技术问题"
                ],
                "sentiment_score": -0.5,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医疗",
                    "生物科技"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "华大基因无创产前检测遭质疑：案例较为复杂，不只是技术问题",
                "Correlation": 9,
                "Sentiment": 4,
                "Importance": 8,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 8,
                "Market_Scope": 3,
                "Time_Proximity": 7,
                "Headline_Structure": 8,
                "Source_Recency": 8
            }
        }
    ]
]